Fig. 5: LINC00675 physically interacts with androgen receptor (AR).

a Schematic diagram outlining the full-length and four different truncated LINC00675 transcripts. b RNA pull-down assay showed that LINC00675 binds to AR in its 737–1530 nt area. c LINC00675 directly interacts with AR protein by RIP assay. Data are represented as mean ± SD. n = 3. d LINC00675 binds to the NT and DBD of AR protein. 293T cells were transfected with pcDNA3.1-AR or pcDNA3.1-AR-truncated plasmids, and harvested after 48 h. RNA pull-down assay and western blot were performed to detect binding of LINC00675 and AR. NT N-terminal, DBD DNA-binding domain, LBD ligand-binding domain. e Silencing LINC00675 suppresses tumor growth in vivo and benefits androgen-deprivation- insensitive models. The dissected tumors show that ASO-targeting LINC00675 reduces tumor weight and mass, and reverses MDV3100 resistance in LNCaP-C4-2b-ENZ cells. Representative images of AR and Ki67 staining of the xenograft tumors indicate that targeting LINC00675 suppresses cell proliferation in vivo by modulating AR expression. Semi-quantitative of AR and Ki67 IHC was analyzed using ImageJ. Data are represented as mean ± SD. n = 5. Scale bar represents 50 μm. ***P < 0.001. ASO antisense oligonucleotides.